Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms?

Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms?

Bibliographic Details
Main Authors:	Taylor, J, Irani, S
Format:	Journal article
Language:	English
Published:	American Medical Association 2017

Similar Items

Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? Does bortezomib inform our understanding of the immunology underlying neuromyelitis optica spectrum disorders?
by: Taylor, J, et al.
Published: (2017)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

Racial differences in neuromyelitis optica spectrum disorder
by: Kim, S, et al.
Published: (2018)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2014)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2013)

Immunological insights into the mechanisms by which RTX is effective in Neuromyelitis Optica spectrum disorders
by: Damato, V, et al.
Published: (2019)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Pittock, S, et al.
Published: (2019)

The evolving clinical spectrum of neuromyelitis optica
by: Viegas, S, et al.
Published: (2008)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
by: George, J, et al.
Published: (2012)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Nour, M, et al.
Published: (2015)

Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G
by: Kim, S-M, et al.
Published: (2017)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

CAN MRI BE USED AS A DIAGNOSTIC TOOL IN NEUROMYELITIS OPTICA SPECTRUM DISORDER?
by: Matthews, L, et al.
Published: (2012)

Characterizing mortality in patients with AQP4‐Ab + neuromyelitis optica spectrum disorder
by: Francis, A, et al.
Published: (2024)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G
by: Kim, S-M, et al.
Published: (2016)

Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
by: Kim, S, et al.
Published: (2013)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
by: Fujihara, K, et al.
Published: (2014)

The borderland of neuromyelitis optica.
by: Matthews, L, et al.
Published: (2009)

Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability
by: Min, J, et al.
Published: (2014)

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
by: Leite, M, et al.
Published: (2012)

Anti-aquaporin 4 antibody-positivity of Korean patients with neuromyelitis optica spectrum disorders
by: Min, J, et al.
Published: (2010)

Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders
by: Damato, V, et al.
Published: (2022)

Prevalence and clinical characteristics of neuromyelitis optica spectrum disorders patients with myelin oligodendrocyte glycoprotein antibodies
by: Sato, D, et al.
Published: (2013)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
by: Kitley, J, et al.
Published: (2014)

Use of mitoxantrone in neuromyelitis optica.
by: Kitley, J, et al.
Published: (2011)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
by: Elsone, L, et al.
Published: (2012)

The Importance of Aquaporin-4 Antibody Assays in Patients beyond the Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2013)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
by: Kitley, J, et al.
Published: (2014)

Neuromyelitis optica spectrum disorder and multiple sclerosis can be distinguished on the basis of MRI brain lesion characteristics
by: Matthews, L, et al.
Published: (2012)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
by: Kitley, J, et al.
Published: (2014)

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders
by: Cheng, F, et al.
Published: (2014)

Neuromyelitis optica in patients with increased interferon alpha concentrations
by: Williams, J, et al.
Published: (2019)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
by: Sedani, S, et al.
Published: (2012)